Reference number(s)
1652-H

SPECIALTY QUANTITY LIMIT PROGRAM

KISQALI (ribociclib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Kisqali (ribociclib) 200 mg tablet	63 tablets per 28 days	Breast Cancer: The recommended dose is 600 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. Dose modifications for adverse reactions: • First dose reduction: Kisqali 400 mg per day for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. • Second dose reduction: Kisqali 200 mg/day for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days.
Kisqali (ribociclib) 600 mg daily dose carton [contains three blister packs with 21 200-mg tablets each]	63 tablets per 28 days	
Kisqali (ribociclib) 400 mg daily dose carton [contains two blister packs with 21 200-mg tablets each]	42 tablets per 28 days	
Kisqali (ribociclib) 200 mg daily dose carton [contains one blister packs with 21 200-mg tablets each]	21 tablets per 28 days	

III. REFERENCE

1. Kisqali [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2020.